Arizona 2026 Regular Session

Arizona Senate Bill SB1752

Introduced
2/5/26  
Report Pass
2/18/26  
Report Pass
2/23/26  

Caption

mescaline; possession; sale; commercial use

Summary

SB1752 adds a new criminal offense in Arizona law targeting mescaline when it is harvested, processed, or made available for commercial use or research. The bill defines “commercial use” broadly to include transactions or uses intended for financial gain, profit, or business-related purposes, and it defines “research” to include medical and pharmaceutical investigation, study, and experimentation. A person who knowingly violates the new section would be guilty of a class 4 felony. The bill also creates a religious-use defense. In a prosecution under the new section, it is a defense if the mescaline is being used or intended for use as part of the bona fide practice of a religious belief, as an integral part of a religious exercise, and in a manner not dangerous to public health, safety, or morals. The bill references the existing statutory definition of mescaline in Arizona’s drug laws and amends Title 13, chapter 34 by adding section 13-3402.01.

Impact

SB1752 would expand Arizona’s controlled-substance enforcement framework by specifically criminalizing the commercial or research-related handling of mescaline, even beyond ordinary possession or sale language. It would create a new class 4 felony offense under Title 13 for knowingly harvesting, processing, or making mescaline available for those purposes, while preserving a narrow religious-use defense. The bill would affect individuals, businesses, and researchers involved with mescaline, including those pursuing medical or pharmaceutical applications, and would likely increase legal risk for any commercial activity involving the substance.

Sentiment

The available voting history suggests generally favorable sentiment toward the bill in the Senate, with the Senate Health and Human Services Committee reporting it out 7-0 and the Senate Third Reading passing 21-7. The Rules Committee action is listed as PFC, indicating procedural movement rather than substantive opposition. Overall, the bill appears to have had meaningful support, though the final floor vote shows some dissent.

Contention

The main point of contention appears to be the bill’s broad restriction on mescaline for “commercial use or research,” which could be seen as reaching medical, pharmaceutical, or other research activities that are not traditionally associated with trafficking. Supporters likely view the measure as a drug-control and public-safety bill, while opponents may be concerned that it could chill legitimate research or business activity involving mescaline. The religious-use defense may also be a point of discussion, as it creates an exception but only under specific conditions tied to bona fide religious practice and public safety.

Companion Bills

No companion bills found.

Previously Filed As

AZ SB1013

Fentanyl; possession; probation ineligibility

AZ SB1370

Civil penalties; commercial motor vehicles

AZ SB1372

Public records; notification; commercial purpose

AZ SB1051

Engineers; alterations; commercial space

AZ SB1290

Brass knuckles; purchase; possession; minors

AZ SB1247

Tobacco use; sale; minimum age

AZ HB2322

Condominiums; commercial structures; residential structures

AZ HB2618

Voluntary prohibited possessor; definition

AZ HCR2034

Firearm sales; transfers; background checks

AZ HB2621

Firearm sales; transfers; background checks

Similar Bills

MI SB0802

Controlled substances: penalties; conduct associated with qualified psychoactive substances; exempt from criminal penalties in certain circumstances. Amends secs. 7401, 7403 & 7404 of 1978 PA 368 (MCL 333.7401 et seq.).

IL SB2772

PSILOCYBIN ADVISORY BOARD

NV SJR10

Urges Congress to take certain actions relating to the therapeutic use of certain psychedelic compounds. (BDR R-801)

CA AB634

Tianeptine.